CATEGORY
Hydroxychloroquine
Beroe LiVE.Ai™
AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Hydroxychloroquine.
Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.
Schedule a DemoHydroxychloroquine Market Monitoring Dashboard
Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™
Schedule a DemoHydroxychloroquine Industry Benchmarks
Savings Achieved
(in %)
The average annual savings achieved in Hydroxychloroquine category is 20.10%
Payment Terms
(in days)
The industry average payment terms in Hydroxychloroquine category for the current quarter is 54.3 days
Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™
Category Strategy and Flexibility
Engagement Model
Supply Assurance
Sourcing Process
Supplier Type
Pricing Model
Contract Length
SLAs/KPIs
Lead Time
Supplier Diversity
Targeted Savings
Risk Mitigation
Financial Risk
Sanctions
AMEs
Geopolitical Risk
Cost Optimization
Price per Unit Competitiveness
Specification Leanness
Minimum Order Quality
Payment Terms
Inventory Control
The World’s first Digital Market Analyst
Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions
Abi is now supercharged with GPT4 AI engine. Enjoy the ease of ChatGPT, now on Abi
Hydroxychloroquine Market Intelligence
global market outlook
- The global Capacity of hydroxychloroquine (HCQ) is 150 MT in 2020 and is expected to grow with a CAGR of ~2 till 2024
- India has accounted for nearly 70 percent of the global production of HCQ. Exports have increased drastically to cater to the global demand
- Demand for HCQ has declined, as new drugs were invented for COVID-19, however, HCQ is always used to treat and manage a number of conditions, such as rheumatoid arthritis and the autoimmune disease called lupus
- Raw materials, such as 4,7 DCQ and HNDA, account for more than 50–60 percent of the price of HCQ. This cost majorly determines the price of the final API/drug
- Sci Pharmtech Inc., Ipca Laboratories Ltd., Cadila Healthcare Ltd., Fermion Oy, Chinoin Pharmaceutical, Amri Rensselaer Inc., Alkaloida Chemical Co. Zrt, Chongqing Kangle Pharmaceutical Co., Ltd., Laurus Labs Ltd., Srini Pharmaceuticals Private Ltd. And Mangalam Drugs are the key players in the market
Use the Hydroxychloroquine market, supplier and price information for category strategy creation and Quaterly Business Reviews (QRBs)
Schedule a DemoHydroxychloroquine market report transcript
Hydroxychloroquine Global Market Outlook:
- India has accounted for nearly 70-80 percent of the global production of HCQ. Exports have increased drastically to cater to the global demand
-
Raw materials account for 50–60 percent of the total cost of production
-
HNDA and 4,7 DCQ are the major raw materials driving the production cost
-
Investing in capacity expansions and equipment are key fixed costs, which are involved in manufacturing of API
Market Overview: HCQ
-
India is the key exporter of HCQ API and formulations to the US, Europe, Brazil, and other western countries.
-
The global HCQ API consumption is estimated at 40–50 MT in 2021, with India accounting for 60–65 percent of the global supply
-
APAC and the US are the key consumption geographies, considering the huge number of affected population
-
Demand for HCQ has declined, as new drugs were invented for COVID-19, however, HCQ is always used to treat and manage a number of conditions, such as rheumatoid arthritis and the autoimmune disease called lupus
Porter's Analysis on Hydroxychloroquine
Supplier Power
-
Supplier power is medium, as the market is fragmented
-
Regulated players have more power, as there are only a few regulated players catering to the regulated markets
Barriers to New Entrants
-
Non-availability of raw material locally is a most common barrier. No other major barriers are identified
Intensity of Rivalry
-
The market is being fragmented, the intensity of rivalry is moderate
-
Competition exists among certified manufacturers to supply HCQ to the developed markets
Threat of Substitutes
-
Glucocorticoids, Immunosuppressant drugs and biologics like Belimumab and rituximab can be used for systemic lupus erythematosus
-
Conventional non-biologic DMARDs like Methotrexate, Leflunomide, Sulfasalazine can be used as alternatives in Rheumatid arthritis
Buyer Power
-
Although several manufacturers are available in the market, choosing a supplier who has DMF or CEP-approved suppliers are crucial
-
Buyer power is moderate, since the number of buyers in the market is also high
Interesting Reads:
Discover the world of market intelligence and how it can elevate your business strategies.
Learn more about how market intelligence can enable informed decision-making, help identify growth opportunities, manage risks, and shape your business's strategic direction.